scholarly journals PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS

2016 ◽  
Vol 58 (0) ◽  
Author(s):  
Marcelo Rosandiski LYRA ◽  
Sonia Regina Lambert PASSOS ◽  
Maria Inês Fernandes PIMENTEL ◽  
Sandro Javier BEDOYA-PACHECO ◽  
Cláudia Maria VALETE-ROSALINO ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Clinical Trial ◽  
Cutaneous Leishmaniasis ◽  
Meglumine Antimoniate ◽  
Pancreatic Toxicity

scholarly journals FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS

2014 ◽  
Vol 56 (4) ◽  
pp. 291-296 ◽  
Author(s):  
Madelon Novato Ribeiro ◽  
Maria Inês Fernandes Pimentel ◽  
Armando de Oliveira Schubach ◽  
Raquel de Vasconcellos Carvalhães de Oliveira ◽  
José Liporage Teixeira ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Cutaneous Leishmaniasis ◽  
Low Dose ◽  
Lower Number ◽  
Adherence To Treatment ◽  
Simple Method ◽  
Meglumine Antimoniate ◽  
Factors Associated ◽  
Adherence Monitoring ◽  
Socioeconomic Data

The favorable outcome of the treatment of a disease is influenced by the adherence to therapy. Our objective was to assess factors associated with adherence to treatment of patients included in a clinical trial of equivalence between the standard and alternative treatment schemes with meglumine antimoniate (MA) in the treatment of cutaneous leishmaniasis (CL), in the state of Rio de Janeiro. Between 2008 and 2011, 57 patients with CL were interviewed using a questionnaire to collect socioeconomic data. The following methods were used for adherence monitoring: counting of vial surplus, monitoring card, Morisky test and modified Morisky test (without the question regarding the schedule); we observed 82.1% (vial return), 86.0% (monitoring card), 66.7% (Morisky test) and 86.0% (modified Morisky test) adherence. There was a strong correlation between the method of vial counting and the monitoring card and modified Morisky test. A significant association was observed between greater adherence to treatment and low dose of MA, as well as with a lower number of people sleeping in the same room. We recommend the use of the modified Morisky test to assess adherence to treatment of CL with MA, because it is a simple method and with a good performance, when compared to other methods.

scholarly journals Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial

2018 ◽  
Vol 113 (9) ◽  
Author(s):  
Dario Brock Ramalho ◽  
Rosiana Estéfane da Silva ◽  
Maria Camilo Ribeiro de Senna ◽  
Hugo Silva Assis Moreira ◽  
Mariana Junqueira Pedras ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Cutaneous Leishmaniasis ◽  
Phase Ii ◽  
Phase Ii Clinical Trial ◽  
Open Label ◽  
Meglumine Antimoniate ◽  
Open Label Phase

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis

Vaccine ◽  
2010 ◽  
Vol 28 (40) ◽  
pp. 6581-6587 ◽  
Author(s):  
Evaldo Nascimento ◽  
Demetrios F. Fernandes ◽  
Edva P. Vieira ◽  
Antonio Campos-Neto ◽  
Jill A. Ashman ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Cutaneous Leishmaniasis ◽  
Meglumine Antimoniate

A double-blind randomized clinical trial of a topical herbal extract (Z-HE) vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in Iran

1999 ◽  
Vol 38 (8) ◽  
pp. 610-612 ◽  
Author(s):  
Fereidoun Zerehsaz ◽  
Rahmat Salmanpour ◽  
Farhad Handjani ◽  
Sadreddine Ardehali ◽  
Mohammad Reza Panjehshahin ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Cutaneous Leishmaniasis ◽  
Randomized Clinical Trial ◽  
Herbal Extract ◽  
Double Blind ◽  
Meglumine Antimoniate
Sign in / Sign up

Export Citation Format

Share Document